News archive
Showing 640 results
November 2016
-
Media ReleaseAlcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meetingThis is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance…
-
Media ReleaseAlcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media ReleaseNovartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved onesTogether in HF social network is an innovative resource for information and support and a place to meet others with similar health experiencesNearly 6 million Americans have heart failure (HF), a…
-
Media ReleaseNovartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
October 2016
-
Media ReleaseNovartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years-- New data at EADV show Cosentyx delivers almost clear or completely clear skin in majority of patients (PASI 90 - 66%, PASI 100 - 44%) after four years of treatment1-- Data show that with Cosentyx…
-
Media ReleaseNovartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
September 2016
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review…
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patientsNew analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media ReleaseNovartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with…
-
Media ReleaseNovartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients